Drug Trial Radar · NCT03266653
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 7, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- New York Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Children's Hospital of Philadelphia; Medical College of Wisconsin; Nationwide Children's Hospital; Indiana University; Washington University School of Medicine; University of California, Los Angeles; University of California, San Francisco
- First posted
- Aug 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Conditions
- Epstein-Barr Virus Infections
- Primary Immune Deficiency Disorder
Interventions
cytotoxic t-lymphocytesDrug
EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Patients will be followed for 12 weeks after each infusion
- Incidence of Response to Treatment [Efficacy]Time frame: Patients will be followed for 12 weeks after each infusion
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Children's Hosptial Los Angeles
Los Angeles, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Johns Hopkins
Baltimore, Maryland · Recruiting
Washington University
St Louis, Missouri · Recruiting
New York Medical College
Valhalla, New York · Recruiting
Nationwide Children's Hosptial
Columbus, Ohio · Recruiting
Children's Hospital of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Medical College of Wisconsin/Children's Hospital of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.